A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Fulvestrant (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 26 Oct 2020 Status changed from active, no longer recruiting to completed.
- 26 Feb 2020 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.
- 05 Feb 2019 Planned End Date changed from 30 Dec 2018 to 31 Dec 2019.